STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (MN-130)	NEXIGURAN
PRONUNCIATION	nex i gur' an
THERAPEUTIC CLAIM	Treatment of transthyretin amyloidosis (ATTR)

CHEMICAL NAMES

RNA (synthetic human transthyretin gene TTR-specific single guide)

all-P-ambo-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-2'-O-methyl-P-thioadenylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')-uridylyl-(3'→5')-adenylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-adenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyl-Pthiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-O-methyluridine

STRUCTURAL FORMULA

1	aaaggcugcu	gaugacaccu	guuuuagagc	uagaaauagc	aaguuaaaau
51	aaggcuaguc	cguuaucaac	uugaaaaagu	ggcaccgagu	cggugcuuuu

MOLECULAR FORMULA $C_{1003}H_{1169}N_{385}Na_{99}O_{687}P_{99}S_6$

TRADEMARKS None

SPONSOR Intellia Therapeutics, Inc.

DESIGNATION CODE hu-G000480 (a component of NTLA-2001)

CAS REGISTRY NUMBER	2305428-07-1
UNII	5G537B4BTJ
WHO NUMBER	12329

SCS